Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

Intellia Therapeutics (NTLA) Reports Q4 Loss of $0.31/Share

March 14, 2017 7:20 AM EDT

Intellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.31), versus ($9.57) reported last year. Revenue for the quarter came in at $5.63 million, versus $1.69 million reported last year.

Financial Guidance

Our primary uses of capital will continue to be research and development services, compensation and related expenses, laboratory and related supplies, legal and other regulatory expenses, patent prosecution filing and maintenance costs for our licensed... More